---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000129"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:46:17.486303+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Immunic announces up to $400M private placement and board changes to fund MS trials

## Summary
- Gross proceeds of up to $400M from private placement led by BVF Partners, with $200M from pre-funded warrants at $0.873 each.
- Proceeds to fund completion of Phase 3 ENSURE trials in relapsing MS and initiation of Phase 3 in primary progressive MS.
- Simona Skerjanec appointed interim chair; Thor Nagel joins board; Maria Törnsén resigns.
- Company entered into royalty purchase agreement with Series B warrant holders for 5% synthetic royalty on vidofludimus calcium sales.
- Company plans to search for new CEO with commercial experience; Dr. Vitt to transition to senior scientific role.

## SEC filing metadata
- accession: 0001193805-26-000129
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/0001193805-26-000129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000129
- JSON: https://secwatch.observer/filing/0001193805-26-000129.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000129.txt

## Key facts
- Material Agreements
  IMMUNIC, INC. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $200 million (effective 2026-02-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $200 million
  - Effective: 2026-02-12
  source text: On February 12, 2026, Immunic Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), pre-funded warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/0001193805-26-000129-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.